BSEResultResults5 Aug 2026
Neuland Laboratories Ltd
Unaudited Financial Results of the Company for the quarter ended June 30, 2026
Neuland Laboratories Ltd has announced its unaudited financial results for the quarter ended June 30, 2026. The company has reported a corporate guarantee of Rs. 40 crores in favour of Gland Pharma Limited for establishing dedicated manufacturing capacity and incurring capital expenditure. Additionally, the company has enhanced its manufacturing capacity at Unit 1 located at Bonthapally Village, Gummadidala Mandal, Sangareddy District, Telangana.
BSEBoard MeetingResults5 Aug 2026
Neuland Laboratories Ltd
Unaudited Financial Results of the Company for the quarter ended June 30, 2026
Neuland Laboratories Ltd has announced unaudited financial results for the quarter ended June 30, 2026, and approved a corporate guarantee of Rs. 40 crores in favour of Gland Pharma Limited for a loan licence agreement. The company also plans to enhance its manufacturing capacity at Unit 1 by 18 KL, with an investment of Rs. 39.8 crores.
BSEAGM/EGMResults4 Aug 2026
Neuland Laboratories Ltd
Voting Results, Scrutinizer Report and proceedings of 42nd Annual General Meeting held on August 4, 2026
Neuland Laboratories Ltd held its 42nd Annual General Meeting on August 4, 2026, through video conferencing. The meeting was attended by 81 members, and the requisite quorum was present. The company declared a final dividend of Rs. 34.00 per equity share, and appointed a new director. The meeting was conducted in accordance with the circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India.
BSEAGM/EGMResults4 Aug 2026
Neuland Laboratories Ltd
Voting Results, Scrutinizer Report and proceeding of 42nd Annual General Meeting held on August 4, 2026
Neuland Laboratories Ltd held its 42nd Annual General Meeting on August 4, 2026, through video conferencing, with 81 members attending. The meeting approved the audited financial statements, declared a final dividend of Rs. 34.00 per equity share, and appointed new directors.
BSECompany UpdateExpansion31 Jul 2026
Neuland Laboratories Ltd
Intimation under Regulation 30 of SEBI Listing Regulations
Neuland Laboratories Ltd has commenced commercial production at two additional capacities under its expansion plans at Unit 1 and Unit 3 in Telangana, India.
BSECompany UpdateResults28 Jul 2026
Neuland Laboratories Ltd
Q1FY27 Earnings Call Intimation
Neuland Laboratories Ltd announces Q1FY27 Earnings Call details, inviting investors to a conference call on August 05, 2026, at 17:30 Hrs (IST). The company has been a leading manufacturer of APIs for over 4 decades, with cGMP certifications from various global authorities.